Alnylam taps RNAi candidate for hemophilia; California Biocom CEO has China on his mind;

@FierceBiotech: Aura BioSciences banks $4.5M from private backers. Report | Follow @FierceBiotech

@JohnCFierce: In matchup with Humira, tofacitinib pill lines up on efficacy, nothing new on safety Bloomberg. News | Follow @JohnCFierce

@RyanMFierce: Sounds like bad news for Seattle-area biotech. Dendreon $DNDN has a conf. call this afternoon to discuss restructuring. Report | Follow @RyanMFierce

> Alnylam Pharmaceuticals ($ALNY) said it has tapped ALN-APC, an RNAi drug for hemophilia, for its program to move its gene-silencing drugs in the clinical development. Release

> Massachusetts has pulled a $750,000 loan--part of its $1 billion life sciences R&D fund--from ECI Biotech because of differences over how the money could be used and changes in the infection-detection company's financial condition. Report

> Given the scant financials of biotech startups makes quantitative analysis difficult for investors; look at qualitative drivers of biotech value--product pipeline, patents, talented management, durable partnerships and access to funds. Item

> "China is big on my mind these days," says Joe Panetta CEO of the southern California Biocom life sciences industry association. "My goal is to build a working relationship between Southern California and China's pharma and device companies." Interview

Pharma News

@FiercePharma: Once again... RT @Loftus: Drugs Beat Stents Against Stroke Recurrence in Study, via @WSJ. Item | Follow @FiercePharma

> Deal-minded analysts eye Bayer, AZ for M&A. Article

> Genzyme apologizes for latest Fabrazyme delay. News 

> Chairman: Ranbaxy set to launch Lipitor as planned. Story  

Vaccines News

> Cuba announces launch of world's first lung cancer vax. News 

> Dendreon cancels GSK Provenge contract. Article

> Related bacterium could create viable TB vax. Story

> Merck finishes animal vaccine plant overhaul. News

> HIV envelope protein approach elicits vaccine immune response. Item

Manufacturing News

> Price overlap blurs quality between generic, substandard drugs. Story

> Pfizer pushes iPads toward factory floor. News

> Brioschi antacid on a comeback, bringing manufacturing jobs to NY. Article

> Labor follows lead of Genzyme, others in green tie-up. Report

> Pharma's cold need is opportunity in all parts of supply chain. Story 

> Study finds quality risk gap between U.S., Puerto Rico plants. News

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.